Having shown that PD-L1+ LEC and monocytic cell populations likely contribute to the immune inhibitory microenvironment in the mammary gland during involution and in breast cancer, we examined whether breast cancer patient samples frequently exhibit co-expression of immune-inhibitory programs and of the LEC marker PDPN and the macrophage marker CD68. This evidence concerns the gene CD68 and breast carcinoma.